OR51B6

Across TCGA pan-cancer cohorts, OR51B6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR51B6 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher OR51B6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR51B6 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

UVM, STAD, and UCEC are the cancer types where OR51B6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	II,III,IV	0.218	0.718	.006	24	view →
STAD	DFS	Median	III,IV	1.000	0.337	.037	12	view →
UCEC	DFS	Median	All	1.000	0.621	.014	12	view →
LUAD	OS	Median	II,III,IV	0.090	0.709	<.001	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	9	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR51B6–UVM (OS)

Open the UVM breakdown →